Vertaling van "prevention of mortality " (Nederlands → Frans) :

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

Bespreking van: Bjelakovic G, Nikolova D, Gluud LL et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.
Analyse de: Bjelakovic G, Nikolova D, Gluud LL et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.

- Centers for Disease Control and Prevention (CDC), Morbidity and Mortality Weekly Report (MMWR).
− Centers for Disease Control and Prevention (CDC), Morbidity and Mortality Weekly Report (MMWR).

Ray KK, Seshasai SRK, Erqou S et al. Statins and all-cause mortality in high-risk primary prevention.
Afilalo J, Duque G, Steele R et al. Statins for secondary prevention in elderly patients.

Bespreking van: Ray KK, Seshasai SRK, Erqou S et al. Statins and all-cause mortality in high-risk primary prevention.
Maron DJ. Review: statins do not reduce mortality in patients with no history of cardiovascular disease.

17.Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.
17. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.

Kaess BM, Vasan RS. Statins are not associated with a decrease in all cause mortality in a high-risk primary prevention setting.
Discussion de: Ray KK, Seshasai SRK, Erqou S et al. Statins and all-cause mortality in high-risk primary prevention.